EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Dose Optimization of Targeted Therapies for Oncologic Indications

Marjorie E Zettler iD

Cancers · 09.06.2024 · 16 (12) · 2180

DOI: 10.3390/cancers16122180 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 09.06.2024. Verfasst von Marjorie E Zettler. Beteiligte Einrichtung: Clinical Science, Accutar Biotechnology Inc., Cranbury, NJ 08512, USA. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic advances in oncology in the 21st century have contributed to significant declines in cancer mortality. Notably, targeted therapies comprised the largest proportion of oncology drugs approved by the United States (US) Food and Drug Administration (FDA) over the past 25 years and have become the standard of care for the treatment of many cancers. However, despite the metamorphosis of the therapeutic landscape, some aspects of cancer drug development have remained essentially unchanged. In particular, the dose-finding methodology originally developed for cytotoxic chemotherapy drugs continues to be implemented, even though this approach no longer represents the most appropriate strategy for modern cancer therapies. In recognition of the need to reconsider assumptions, adapt the dose selection process for newer drugs, and design alternative strategies, the FDA has undertaken several initiatives in recent years to address these concerns. These actions include the launch of Project Optimus in 2021 and the issuance of draft guidance for industry on dose optimization of oncology drugs in 2023. Amid this evolving regulatory environment, the present manuscript reviews case studies for six different targeted cancer therapies, highlighting how dose-finding challenges have been managed to date by oncologists, sponsors, and regulators.

Schlagwörter

Stichwörter der Autor:innen

cancer drugsdose optimizationdose-findingdrug developmentoncology drugstargeted therapy

Autor:innen und Institutionen

  • Clinical Science, Accutar Biotechnology Inc., Cranbury, NJ 08512, USA.

ORCID-Profile: Marjorie E Zettler

Zitieren

APA

Zettler, M. E. (2024). Dose Optimization of Targeted Therapies for Oncologic Indications. Cancers, 16(12), 2180. https://doi.org/10.3390/cancers16122180

Vancouver

Zettler ME. Dose Optimization of Targeted Therapies for Oncologic Indications. Cancers. 2024;16(12):2180. doi:10.3390/cancers16122180

BibTeX
@article{Zettler2024,
  author = {Zettler, Marjorie E},
  title = {Dose Optimization of Targeted Therapies for Oncologic Indications},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {12},
  pages = {2180},
  doi = {10.3390/cancers16122180}
}
Kostenlos starten →